Kanya Rajangam is Pres. & Chief Med. & Dev. Off. of Senti Biosciences, Inc.. Currently has a direct ownership of 86,984 shares of SNTI, which is worth approximately $280,088. The most recent transaction as insider was on Mar 07, 2025, when has been sold 78,363 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 87K
13.88% 3M change
13.88% 12M change
Total Value Held $280,088

Kanya Rajangam Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 07 2025
BUY
Grant, award, or other acquisition
-
78,363 Added 47.39%
86,984 Common Stock
Feb 06 2025
SELL
Open market or private sale
$795 $4.37 p/Share
182 Reduced 2.07%
8,621 Common Stock
Feb 04 2025
SELL
Open market or private sale
$5,278 $4.07 p/Share
1,297 Reduced 12.84%
8,803 Common Stock
Feb 01 2024
BUY
Grant, award, or other acquisition
-
101,000 Added 50.0%
101,000 Common Stock

Also insider at

NKTX
Nkarta, Inc. Healthcare
TSBX
Turnstone Biologics Corp.
KR

Kanya Rajangam

Pres. & Chief Med. & Dev. Off.
South San Francisco, CA

Track Institutional and Insider Activities on SNTI

Follow Senti Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SNTI shares.

Notify only if

Insider Trading

Get notified when an Senti Biosciences, Inc. insider buys or sells SNTI shares.

Notify only if

News

Receive news related to Senti Biosciences, Inc.

Track Activities on SNTI